Choosing wisely: Review and commentary on anti-nuclear antibody (ANA) testing

Autoimmunity Reviews

Volumn 15, Issue 3, 2016, Pages 272-280

  Fritzler, Marvin J ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

ANA subserology; Antinuclear antibodies; Choosing wisely; Extractable nuclear antibodies; Health care expenditures

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY;

DISEASE ACTIVITY; HEALTH CARE COST; HUMAN; IMMUNOASSAY; MEDICAL SOCIETY; PATIENT MONITORING; REVIEW; RHEUMATOLOGY; SEROLOGY; ARTHRITIS, RHEUMATOID; IMMUNOLOGY;

ANTIBODIES, ANTINUCLEAR; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; HUMANS;

EID: 84958905708     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2015.12.002     Document Type: Review

References (105)

1. Levinson W., Kallewaard M., Bhatia R.S., Wolfson D., Shortt S., Kerr E.A. 'Choosing wisely': a growing international campaign. BMJ Qual Saf 2015, 24:167-174.
2. OECD.org/health Focus on Health Spending: OECD Statistics 2015 http://www.OECD.org/health.
3. OECD Health Data: Health Expenditure and Financing http://www.oecd-ilibrary.org/social-issues-migration-health/total-expenditure-on-health_20758480-table1.
4. Cassel C.K., Guest J.A. Choosing wisely: helping physicians and patients make smart decisions about their care. JAMA 2012, 307:1801-1802.
5. Mason D.J. Choosing wisely: changing clinicians, patients, or policies?. JAMA 2015, 313:657-658.
6. Fenton J.J., Franks P., Feldman M.D., Jerant A., Henry S.G., Paterniti D.A., et al. Impact of patient requests on provider-perceived visit difficulty in primary care. J Gen Intern Med 2015, 30:214-220.
7. Brett A.S., McCullough L.B. Addressing requests by patients for nonbeneficial interventions. JAMA 2012, 307:149-150.
8. Campbell E.G., Regan S., Gruen R.L., Ferris T.G., Rao S.R., Cleary P.D., et al. Professionalism in medicine: results of a national survey of physicians. Ann Intern Med 2007, 147:795-802.
9. Greenwald R. And a diagnostic test was performed. N Engl J Med 2005, 353:2089-2090.
10. Bussone G., Mouthon L. Autoimmune manifestations in primary immune deficiencies. Autoimmun Rev 2009, 8:332-336.
11. Tang H., Ng J.H. Googling for a diagnosis-use of Google as a diagnostic aid: internet based study. BMJ 2006, 333:1143-1145.
12. Doyle-Lindrud S. Watson will see you now: a supercomputer to help clinicians make informed treatment decisions. Clin J Oncol Nurs 2015, 19:31-32.
13. Ghahramani Z. Probabilistic machine learning and artificial intelligence. Nature 2015, 521:452-459.
14. Crown W.H. Potential application of machine learning in health outcomes research and some statistical cautions. Value Health 2015, 18:137-140.
15. ABIM Foundation ABoIMA-AFAoP-ASoIMEFoI Medical professionalism in the new millennium: a physician charter. Ann Intern Med 2002, 136:243-246.
16. Yazdany J., Schmajuk G., Robbins M., Daikh D., Beall A., Yelin E., et al. Choosing wisely: the American College of Rheumatology's Top 5 list of things physicians and patients should question. Arthritis Care Res (Hoboken) 2013, 65:329-339.
17. Chow S.L., Thorne J.C., Bell M.J., Ferrari R., Bagheri Z., Boyd T., et al. Choosing wisely: the Canadian Rheumatology Association's list of 5 items physicians and patients should question. J Rheumatol 2015, 42:682-689.
18. Meroni P.L., Schur P.H. ANA screening: an old test with new recommendations. Ann Rheum Dis 2010, 69:1420-1422.
19. American College of Rheumatology Position Statement, methodology of testing for antinuclear antibodies http://www.rheumatology.org/Portals/0/Files/Methodology%20of%20Testing%20Antinuclear%20Antibodies%20Position%20Statement.pdf.
20. Fritzler M.J. The antinuclear antibody (ANA) test: last or lasting gasp?. Arthritis Rheum 2011, 16:19-22.
21. Solomon D.H., Kavanaugh A.J., Schur P.H. Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Rheum 2002, 47:434-444.
22. Mahler M., Meroni P.L., Bossuyt X., Fritzler M.J. Current concepts and future directions for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. J Immunol Res 2014, 2014:315179.
23. Damoiseaux J., Andrade L.E., Fritzler M.J., Shoenfeld Y. Autoantibodies 2015: from diagnostic biomarkers toward prediction, prognosis and prevention. Autoimmun Rev 2015, 14:555-563.
24. Bizzaro N., Tozzoli R., Villalta D. Autoimmune diagnostics: the technology, the strategy and the clinical governance. Immunol Res 2015, 61:126-134.
25. Copple S.S., Jaskowski T.D., Giles R., Hill H.R. Interpretation of ANA indirect immunofluorescence test outside the darkroom using NOVA view compared to manual microscopy. J Immunol Res 2014, 2014:149316.
26. Meroni P.L., Bizzaro N., Cavazzana I., Borghi M.O., Tincani A. Automated tests of ANA immunofluorescence as throughput autoantibody detection technology: strengths and limitations. BMC Med 2014, 12:38-12.
27. Abeles A.M., Abeles M. The clinical utility of a positive antinuclear antibody test result. Am J Med 2013, 126:342-348.
28. Fitch-Rogalsky C., Steber W., Mahler M., Lupton T., Martin L., Barr S.G., et al. Clinical and serological features of patients referred through a rheumatology triage system because of positive antinuclear antibodies. PLoS One 2014, 9.
29. Mahler M., Fritzler M.J. The clinical significance of the dense fine speckled immunofluorescence pattern on HEp-2 cells for the diagnosis of systemic autoimmune diseases. Clin Dev Immunol 2012, 2012:494356.
30. Lopez-Hoyos M., Cabeza R., Martinez-Taboada V.M., Crespo J., SanSegundo D., Blanco R., et al. Clinical disease activity and titers of anti-dsDNA antibodies measured by an automated immunofluorescence assay in patients with systemic lupus erythematosus. Lupus 2005, 14:505-509.
31. Cozzani E., Drosera M., Gasparini G., Parodi A. Serology of lupus erythematosus: correlation between immunopathological features and clinical aspects. Autoimmune Dis 2014, 2014:321359.
32. Fu S.M., Dai C., Zhao Z., Gaskin F. Anti-dsDNA antibodies are one of the many autoantibodies in systemic lupus erythematosus. F1000Res 2015, 4:939.
33. Ogasawara M., Shikishima K., Sakai T., Takagi M., Tanaka K. A case of neuromyelitis optica developing into myelitis 25 years after optic neuritis. Jpn J Ophthalmol 2010, 54:372-373.
34. Grootscholten C., Dieker J.W., McGrath F.D., Roos A., Derksen R.H., van d V., et al. A prospective study of anti-chromatin and anti-C1q autoantibodies in patients with proliferative lupus nephritis treated with cyclophosphamide pulses or azathioprine/methylprednisolone. Ann Rheum Dis 2006, 66:693-696.
35. Agmon-Levin N., Damoiseaux J., Kallenberg C., Sack U., Witte T., Herold M., et al. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis 2014, 73:17-23.
36. Sperotto F., Cuffaro G., Brachi S., Seguso M., Zulian F. Prevalence of antinuclear antibodies in schoolchildren during puberty and possible relationship with musculoskeletal pain: a longitudinal study. J Rheumatol 2014, 41:1405-1408.
37. Mahler M., Fritzler M.J. Antinuclear antibodies in children. J Rheumatol 2014, 41:1260-1262.
38. Hu-Torres S., Foster C.S. Disease of the year: juvenile idiopathic arthritis-differential diagnosis. Ocul Immunol Inflamm 2014, 22:42-55.
39. Heiligenhaus A., Heinz C., Edelsten C., Kotaniemi K., Minden K. Review for disease of the year: epidemiology of juvenile idiopathic arthritis and its associated uveitis: the probable risk factors. Ocul Immunol Inflamm 2013, 21:180-191.
40. Zierhut M., Heiligenhaus A., deBoer J., Cunningham E.T., Tugal-Tutkun I. Controversies in juvenile idiopathic arthritis-associated uveitis. Ocul Immunol Inflamm 2013, 21:167-179.
41. Man A., Shojania K., Phoon C., Pal J., de Badyn M.H., Pi D., et al. An evaluation of autoimmune antibody testing patterns in a Canadian health region and an evaluation of a laboratory algorithm aimed at reducing unnecessary testing. Clin Rheumatol 2013, 32:601-608.
42. Lesuis N., Hulscher M.E., Piek E., Demirel H., Laan-Baalbergen N., Meek I., et al. Choosing wisely in daily practice: an intervention study on antinuclear antibody testing by rheumatologists. Arthritis Care Res (Hoboken) 2015, [ePub ahead of print].
43. Schouwers S., Bonnet M., Verschueren P., Westhovens R., Blockmans D., Marien G., et al. Value-added reporting of antinuclear antibody testing by automated indirect immunofluorescence analysis. Clin Chem Lab Med 2014, 52:547-551.
44. Yelin E., Cisternas M.G., Pasta D.J., Trupin L., Murphy L., Helmick C.G. Medical care expenditures and earnings losses of persons with arthritis and other rheumatic conditions in the United States in 1997: total and incremental estimates. Arthritis Rheum 2004, 50:2317-2326.
45. Panopalis P., Gillis J.Z., Yazdany J., Trupin L., Hersh A., Julian L., et al. Frequent use of the emergency department among persons with systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2010, 62:401-408.
46. Turchetti G., Yazdany J., Palla I., Yelin E., Mosca M. Systemic lupus erythematosus and the economic perspective: a systematic literature review and points to consider. Clin Exp Rheumatol 2012, 30:S116-S122.
47. Lee J., Peschken C.A., Muangchan C., Silverman E., Pineau C., Smith C.D., et al. The frequency of and associations with hospitalization secondary to lupus flares from the 1000 faces of lupus Canadian cohort. Lupus 2013, 22:1341-1348.
48. Furst D.E., Clarke A., Fernandes A.W., Bancroft T., Gajria K., Greth W., et al. Medical costs and healthcare resource use in patients with lupus nephritis and neuropsychiatric lupus in an insured population. J Med Econ 2013, 16:500-509.
49. McCarthy M. US Choosing Wisely campaign has had only modest success, study finds. BMJ 2015, 351:h5437.
50. Rosenberg A., Agiro A., Gottlieb M., Barron J., Brady P., Liu Y., et al. Early trends among seven recommendations from the choosing wisely campaign. JAMA Intern Med 2015, 1-9.
51. Smoldt R.K., Cortese D.A. Pay-for-performance or pay for value?. Mayo Clin Proc 2007, 82:210-213.
52. Cortese D.A. A vision of individualized medicine in the context of global health. Clin Pharmacol Ther 2007, 82:491-493.
53. Rouse W.B., Johns M.E., Cortese D.A. Healthcare costs or investments?. Stud Health Technol Inform 2010, 153:479-480.
54. Mahler M., Miller F.W., Fritzler M.J. Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review. Autoimmun Rev 2014, 13:367-371.
55. Bahrt K.M., McCarty G.A. A negative fluorescent antinuclear antibody test in a patient with Jo-1 antibody. J Rheumatol 1985, 12:624-625.
56. Mahler M., Dervieux T. Comments on recent advances and recommendations for the assessment of autoantibodies to cellular antigens referred as antinuclear antibodies. Ann Rheum Dis 2014, 73.
57. Copple S.S., Martins T.B., Masterson C., Joly E., Hill H.R. Comparison of three multiplex immunoassays for detection of antibodies to extractable nuclear antibodies using clinically defined sera. Ann N Y Acad Sci 2007, 1109:464-472.
58. Op De Beéck K., Vermeersch P., Verschueren P., Westhovens R., Marien G., Blockmans D., et al. Detection of antinuclear antibodies by indirect immunofluorescence and by solid phase assay. Autoimmun Rev 2011, 10:801-808.
59. Svegliati S., Cancello R., Sambo P., Luchetti M., Paroncini P., Orlandini G., et al. Platelet-derived growth factor and reactive oxygen species (ROS) regulate Ras protein levels in primary human fibroblasts via ERK1/2. Amplification of ROS and Ras in systemic sclerosis fibroblasts. J Biol Chem 2005, 280:36474-36482.
60. Fritzler M.J., Fritzler M.L. The emergence of multiplexed technologies as diagnostic platforms in systemic autoimmune diseases. Curr Med Chem 2006, 13:2503-2512.
61. Fritzler M.J., Fritzler M.L. Microbead-based technologies in diagnostic autoantibody detection. Expert Opin Med Diag 2009, 3:81-89.
62. Dahle C., Skogh T., Aberg A.K., Jalal A., Olcen P. Methods of choice for diagnostic antinuclear antibody (ANA) screening: benefit of adding antigen-specific assays to immunofluorescence microscopy. J Autoimmun 2004, 22:241-248.
63. Hoffman I.E., Peene I., Veys E.M., De K.F. Detection of specific antinuclear reactivities in patients with negative anti-nuclear antibody immunofluorescence screening tests. Clin Chem 2002, 48:2171-2176.
64. Fritzler M.J., Hanson C., Miller J., Eystathioy T. Specificity of autoantibodies to SS-A/Ro on a transfected and overexpressed human 60 kDa Ro autoantigen substrate. J Clin Lab Anal 2002, 16:103-108.
65. Schulte-Pelkum J., Fritzler M., Mahler M. Latest update on the Ro/SS-A autoantibody system. Autoimmun Rev 2009, 8:632-637.
66. Fritzler M.J., Wiik A., Fritzler M.L., Barr S.G. The use and abuse of commercial kits used to detect autoantibodies. Arthritis Res Ther 2003, 5:192-201.
67. Wiik A.S., Gordon T.P., Kavanaugh A.F., Lahita R.G., Reeves W., Van Venrooij W.J., et al. Cutting edge diagnostics in rheumatology: on the role of patients, clinicians, and laboratory scientists in optimizing the use of autoimmune serology. Arthritis Care Res 2004, 51:291-298.
68. Ochs R.L., Mahler M., Basu A., Rios-Colon L., Sanchez T.W., Andrade L.E., et al. The significance of autoantibodies to DFS70/LEDGFp75 in health and disease: integrating basic science with clinical understanding. Clin Exp Med 2015, [EPub aheadd of print].
69. Mahler M., Meroni P.L., Andrade L.E., Khamashta M., Bizzaro N., Casiano C.A., et al. Towards a better understanding of the clinical association of anti-DFS70 autoantibodies. Autoimmun Rev 2015, [ePub ahead of print].
70. Kavanaugh A., Tomar R., Reveille J., Solomon D.H., Homburger H.A. Guidelines for clinical use of the antinuclear antibody test and tests for specific autoantibodies to nuclear antigens. American College of Pathologists. Arch Pathol Lab Med 2000, 124:71-81.
71. Tozzoli R., Bizzaro N., Tonutti E., Villalta D., Bassetti D., Manoni F., et al. Guidelines for the laboratory use of autoantibody tests in the diagnosis and monitoring of autoimmune rheumatic diseases. Am J Clin Pathol 2002, 117:316-324.
72. British Columbia Ministry of Health Antinuclear antibody (ANA) testing for connective tissue disease http://www.bcguidelines.ca/guideline_ana_testing.html.
73. Rose N.R. Prediction and prevention of autoimmune disease: a personal perspective. Ann N Y Acad Sci 2007, 1109:117-128.
74. Bizzaro N., Tozzoli R., Shoenfeld Y. Are we at a stage to predict autoimmune rheumatic diseases?. Arthritis Rheum 2007, 56:1736-1744.
75. Deane K.D., El-Gabalawy H. Pathogenesis and prevention of rheumatic disease: focus on preclinical RA and SLE. Nat Rev Rheumatol 2014, 10:212-228.
76. Theander E., Jonsson R., Sjostrom B., Brokstad K., Olsson P., Henriksson G. Autoantibody profiling can predict primary Sjogren's syndrome years before diagnosis and identify those with early onset and severe disease course. Arthritis Rheum 2015.
77. Gan R.W., Trouw L.A., Shi J., Toes R.E., Huizinga T.W., Demoruelle M.K., et al. Anti-carbamylated protein antibodies are present prior to rheumatoid arthritis and are associated with its future Diagnosis. J Rheumatol 2015, [jrheum].
78. Arbuckle M.R., McClain M.T., Rubertone M.V., Scofield R.H., Dennis G.J., James J.A., et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003, 349:1526-1533.
79. Heinlen L.D., Ritterhouse L.L., McClain M.T., Keith M.P., Neas B.R., Harley J.B., et al. Ribosomal P autoantibodies are present before SLE onset and are directed against non-C-terminal peptides. J Mol Med 2010.
80. Heinlen L.D., McClain M.T., Ritterhouse L.L., Bruner B.F., Edgerton C.C., Keith M.P., et al. 60 kD Ro and nRNP a frequently initiate human lupus autoimmunity. PLoS One 2010, 5.
81. Heinlen L.D., McClain M.T., Merrill J., Akbarali Y.W., Edgerton C.C., Harley J.B., et al. Clinical criteria for systemic lupus erythematosus precede diagnosis, and associated autoantibodies are present before clinical symptoms. Arthritis Rheum 2007, 56:2344-2351.
82. Jonsson R., Theander E., Sjostrom B., Brokstad K., Henriksson G. Autoantibodies present before symptom onset in primary Sjogren syndrome. JAMA 2013, 310:1854-1855.
83. Theander E., Jonsson R., Sjostrom B., Brokstad K., Olsson P., Henriksson G. Prediction of Sjogren's syndrome years before diagnosis and identification of patients with early onset and severe disease course by autoantibody profiling. Arthritis Rheum 2015, 67:2427-2436.
84. Al D.M., Massarotti E.M., Fine A., Tsao H., Ho P., Schur P.H., et al. Development of SLE among "potential SLE" patients seen in consultation: long-term follow-up. Int J Clin Pract 2014, 68:1508-1513.
85. Costenbader K.H., Schur P.H. We need better classification and terminology for "people at high-risk of or in the process of developing lupus". Arthritis Care Res (Hoboken) 2015, 67:593-596.
86. Relle M., Weinmann-Menke J., Scorletti E., Cavagna L., Schwarting A. Genetics and novel aspects of therapies in systemic lupus erythematosus. Autoimmun Rev 2015, 14:1005-1018.
87. Hagberg N., Ronnblom L. Systemic lupus erythematosus-a disease with a dysregulated type I interferon system. Scand J Immunol 2015, 82:199-207.
88. Patel V., Assassi S., Mayes M.D., Feghali-Bostwick C.A. Anti-RNA polymerase II antibodies in a U.S. Cohort of systemic sclerosis patients: comment on the article by hamaguchi et al. Arthritis Rheum 2015, 67:2547-2548.
89. Deane K.D. Can rheumatoid arthritis be prevented?. Best Pract Res Clin Rheumatol 2013, 27:467-485.
90. Finckh A., Deane K.D. Prevention of rheumatic diseases: strategies, caveats, and future directions. Rheum Dis Clin North Am 2014, 40:771-785.
91. Robertson J.M., James J.A. Preclinical systemic lupus erythematosus. Rheum Dis Clin North Am 2014, 40:621-635.
92. Mekinian A., Costedoat-Chalumeau N., Masseau A., Tincani A., De C.S., Alijotas-Reig J., et al. Obstetrical APS: is there a place for hydroxychloroquine to improve the pregnancy outcome?. Autoimmun Rev 2015, 14:23-29.
93. van Nies J.A., Krabben A., Schoones J.W., Huizinga T.W., Kloppenburg M., van der Helm-van Mil A.H. What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review. Ann Rheum Dis 2014, 73:861-870.
94. Klein M., Mann H., Plestilova L., Betteridge Z., Mchugh N., Remakova M., et al. Arthritis in idiopathic inflammatory myopathy: clinical features and autoantibody associations. J Rheumatol 2014, 41:1133-1139.
95. Ferrari R. Evaluation of the Canadian Rheumatology Association Choosing Wisely recommendation concerning anti-nuclear antibody (ANA) testing. Clin Rheumatol 2015.
96. Hochberg M.C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997, 40:1725.
97. Petri M., Orbai A.M., Alarcon G.S., Gordon C., Merrill J.T., Fortin P.R., et al. Derivation and validation of systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012, 64:2677-2686.
98. Yoshizaki A., Komura K., Iwata Y., Ogawa F., Hara T., Muroi E., et al. Clinical significance of serum HMGB-1 and sRAGE levels in systemic sclerosis: association with disease severity. J Clin Immunol 2009, 29:180-189.
99. Damoiseaux J., Agmon-Levin N., Van B.M., Chopyak V., Eriksson C., Heijnen I., et al. From ANA-screening to antigen-specificity: an EASI-survey on the daily practice in European countries. Clin Exp Rheumatol 2014, 32:539-546.
100. Bossuyt X., Cooreman S., De B.H., Verschueren P., Westhovens R., Blockmans D., et al. Detection of antinuclear antibodies by automated indirect immunofluorescence analysis. Clin Chim Acta 2013, 415:101-106.
101. Avery T.Y., van de Cruys M., Austen J., Stals F., Damoiseaux J.G. Anti-nuclear antibodies in daily clinical practice: prevalence in primary, secondary, and tertiary care. J Immunol Res 2014, 2014:401739.
102. Thomson K.F., Murphy A., Goodfield M.J., Misbah S.A. Is it useful to test for antibodies to extractable nuclear antigens in the presence of a negative antinuclear antibody on Hep-2 cells?. J Clin Pathol 2001, 54:413.
103. Cross L.S., Aslam A., Misbah S.A. Antinuclear antibody-negative lupus as a distinct diagnostic entity-does it no longer exist?. QJM 2004, 97:303-308.
104. Slater C.A., Davis R.B., Shmerling R.H. Antinuclear antibody testing: a study of clinical utility. Arch Intern Med 1996, 156:1421-1425.
105. Bossuyt X., Luyckx A. Antibodies to extractable nuclear antigens in antinuclear antibody-negative samples. Clin Chem 2005, 51:2426-2427.